XenoGesis is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.
It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically, XenoGesis can identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.
We combine our state-of-the-art in vitro, in vivo and bioanalytical capabilities with our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services.
Using this integrated approach we provide you with the information required to successfully achieve your drug discovery goals.
XenoGesis was acquired by Sygnature Discovery in September 2020.
AGINKO Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development.
Given our expertise, know-how, and network in the field of osteoarticular pathologies, AGINKO today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.
BioCentrum's mission is to create a platform for our clients and partners in order to help them translate innovative discoveries into preclinical candidates with improved chances to become marketed in the least amount of time possible. Our offer is a range of in vitro and in vivo assays that are created toward incorporating preclinical information into your pipeline.
Admescope is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with premium quality tailor-made services to drug discovery in the area of ADME-Tox.
The service offering is widely spread, from highly tailored and optimised studies to high-throughput screening. Admescope’s unique expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis. The right level of research can always be found for the customer whether in the discovery or lead optimisation phase.
All of the services include comprehensive study consulting which enables tailoring the study according to customers’ specific needs. The state-of-art quality data is ensured by optimising the conditions according to the compounds instead of using generic protocols. All of the data can be interpreted for the customer and helped to understand the real meaning of the numerical values and observations.
• in vitro Metabolism
• in vivo DMPK
• Drug Interactions
• Quantitative Bioanalysis
• Permeability & Transporters
• Physicochemistry & Binding
• in vitro Toxicology
ANS Biotech, a preclinical CRO dedicated to pain pharmacology, supports drug discovery and development efforts of companies involved in human and animal health, food and nutrition, by providing them with:
• Clinically relevant in vivo models for successful R&D of innovative analgesics, especially in the field of inflammatory pain, neuropathic pain and visceral pain ;
• Customized scientific studies meeting drug discovery and development objectives ;
• Consulting activities.
ANS Biotech also offers ALGOGramTM, a unique in vivo screening tool that provides a rapid and cost-effective means to systematically explore pain indications for compounds. ALGOGramTM is designed to help you make critical “go / no go” decisions during the early screening phase of a project.